Michela Adamo

Michela Adamo

Auto-generated profile, based on publicly available information

Michela Adamo

Department of Endocrinology, Diabetology, and Metabolism, Lausanne University Hospital, Lausanne, Switzerland

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 September 2022 in Science
Verified
Journal Article
Closed access
MMMaria Manfredi-Lozano
Maria Manfredi-Lozano
VLValerie Leysen
Valerie Leysen
MAMichela Adamo
Michela Adamo
IPIsabel Paiva
Isabel Paiva
RRRENAUD ROVERA
RENAUD ROVERA
VPVincent Prévot
Vincent Prévot
At the present time, no viable treatment exists for cognitive and olfactory deficits in Down syndrome (DS). We show in a DS model (Ts65Dn mice) that these progressive nonreproductive neurological symptoms closely parallel a postpubertal decrease in hypothalamic as well as extrahypothalamic expression of a master molecule that controls reproduction—gonadotropin-releasing hormone (GnRH)—and appear related to an imbalance in a microRNA-gene network known to regulate GnRH neuron maturation together with altered hippocampal synaptic transmission. Epigenetic, cellular, chemogenetic, and pharmacological interventions that restore physiological GnRH levels abolish olfactory and cognitive defects in Ts65Dn mice, whereas pulsatile GnRH therapy improves cognition and brain connectivity in adult DS patients. GnRH thus plays a crucial role in olfaction and cognition, and pulsatile GnRH therapy holds promise to improve cognitive deficits in DS.

8 April 2019 in Diabetes, Obesity and Metabolism
Verified
Journal Article
Closed access
PDF file
AFAnna Ferrulli
Anna Ferrulli
CMConcetta Macrì
Concetta Macrì
ITIleana Terruzzi
Ileana Terruzzi
SMStefano Massarini
Stefano Massarini
FAFederico Ambrogi
Federico Ambrogi
Livio LuziLivio Luzi
Livio Luzi

1 January 2017 in Cell Transplantation
Verified
Journal Article
Open access
MAM. Adamo
M. Adamo
Roberto CodellaRoberto Codella
Roberto Codella
FCF. Casiraghi
F. Casiraghi
AFAnna Ferrulli
Anna Ferrulli
CMC. Macrì
C. Macrì
LLL. Luzi
L. Luzi
Previous studies in humans with type 1 diabetes mellitus (T1D) and in nonobese diabetic mice have investigated the beneficial immunomodulatory potential of aerobic physical activity. Performing high volume of aerobic exercise may favorably regulate autoimmunity in diabetes. We tested whether increased physical activity is a self-sufficient positive factor in T1D subjects. During a 3-month observational period, active (six males; 40.5 ± 6.1 years; BMI: 24.5 ± 2.1) and sedentary (four males, three females; 35.9 ± 8.9 years; BMI: 25.7 ± 3.8) T1D individuals on insulin pump therapy were studied for metabolic, inflammatory, and autoimmune parameters. At baseline and at the end of a 3-month period, glycosylated hemoglobin (HbA1c), autoantibodies (anti-GAD, anti-ZnT8, anti-IA2, and ICA) and proinflammatory cytokines (IL-6 and TNF-α) were evaluated. During the third month of the period, physically active T1D patients showed a significant reduction in the average glucose levels (-9%, p = 0.025, by CGM) compared to the first month values, and even their hyperglycemic episodes (>180 mg/dl) diminished significantly (-24.2%, p = 0.032 vs. first month). Moreover, active T1D subjects exhibited an improved body composition with respect to sedentary controls. No significant changes were detected as to the autoimmune and inflammatory profiles. This study confirms the beneficial role of physical exercise associated with insulin pump therapy in order to improve metabolic control in individuals with T1D. These preliminary positive observations need to be challenged in a prolonged interventional follow-up.

8 November 2018 in Endocrine
Verified
Journal Article
Closed access
PDF file
AFAnna Ferrulli
Anna Ferrulli
CMConcetta Macrì
Concetta Macrì
ITIleana Terruzzi
Ileana Terruzzi
FAFederico Ambrogi
Federico Ambrogi
VMValentina Milani
Valentina Milani
Livio LuziLivio Luzi
Livio Luzi

19 June 2017 in Journal of Diabetes Research
Verified
Journal Article
Open access
PDF file
Roberto CodellaRoberto Codella
Roberto Codella
SBStefano Benedini
Stefano Benedini
SPStefano Paini
Stefano Paini
ACAndrea Caumo
Andrea Caumo
MAMichela Adamo
Michela Adamo
Livio LuziLivio Luzi
Livio Luzi
We investigated the effects of glucose and diverse breakfasts on glucose increment and ghrelin suppression and cognitive processing of sensory information assessed by frontal P300 evoked potentials. In a randomized crossover design, 12 healthy individuals (6M/6F; BMI 22.2 ± 0.4 kg/m2; 27 ± 1.3 years, mean ± SEM) underwent 50 g OGTT (A) and 3 breakfasts (B1: milk and cereals; B2: milk, apple, and chocolate cream-filled sponge cake; B3: milk, apple, bread, and hazelnut chocolate cream) to assess plasma glucose-, insulin-, and ghrelin excursions. An electroencephalography was performed before and 100 min after consumption of each load to measure the latency of frontal P300 evoked potentials as index of cognitive performance. Breakfasts B1 and B2 exhibited significantly lower glycemic and insulinemic responses as compared to A. Breakfast B3 exhibited significantly lower glycemic, but not insulinemic response, as compared to A. Final plasma ghrelin inhibition was more pronounced, albeit not significantly, in all breakfasts with respect to A. P300 latency tended to decrease following each of the three breakfasts, but B3 was the only breakfast capable to elicit a statistically significant reduction in P300 latency with respect to A (p<0.01), suggesting ameliorated cognitive performance. Such amelioration was correlated with the 2-hour final inhibition of plasma ghrelin concentration (r=0.61,p=0.01).

23 November 2016 in Acta Diabetologica
Verified
Journal Article
Closed access
PDF file
Roberto CodellaRoberto Codella
Roberto Codella
MAMichela Adamo
Michela Adamo
PMPaola Maffi
Paola Maffi
LPLorenzo Piemonti
Lorenzo Piemonti
ASAntonio Secchi
Antonio Secchi
Livio LuziLivio Luzi
Livio Luzi